MX2021002014A - Metodo para determinar el riesgo de recidiva de cancer de mama. - Google Patents

Metodo para determinar el riesgo de recidiva de cancer de mama.

Info

Publication number
MX2021002014A
MX2021002014A MX2021002014A MX2021002014A MX2021002014A MX 2021002014 A MX2021002014 A MX 2021002014A MX 2021002014 A MX2021002014 A MX 2021002014A MX 2021002014 A MX2021002014 A MX 2021002014A MX 2021002014 A MX2021002014 A MX 2021002014A
Authority
MX
Mexico
Prior art keywords
breast cancer
cancer recurrence
predicting breast
methods
subject afflicted
Prior art date
Application number
MX2021002014A
Other languages
English (en)
Inventor
Brock Schroeder
Yi Zhang
Catherine A Schnabel
Dennis C Sgroi
Mark G Erlander
Original Assignee
Bio Theranostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Theranostics Inc filed Critical Bio Theranostics Inc
Publication of MX2021002014A publication Critical patent/MX2021002014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Se proporcionan métodos para determinar el riesgo de recidiva del cáncer en un sujeto que padece cáncer de mama. También se proporcionan métodos para determinar la capacidad de respuesta al tratamiento de un sujeto que padece cáncer de mama. Adicionalmente, se proporcionan métodos para el tratamiento de un sujeto que padece cáncer de mama.
MX2021002014A 2013-09-11 2016-03-04 Metodo para determinar el riesgo de recidiva de cancer de mama. MX2021002014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361876757P 2013-09-11 2013-09-11

Publications (1)

Publication Number Publication Date
MX2021002014A true MX2021002014A (es) 2021-04-28

Family

ID=52666241

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002938A MX2016002938A (es) 2013-09-11 2014-09-10 Prediccion de la recidiva del cáncer de mama.
MX2021002014A MX2021002014A (es) 2013-09-11 2016-03-04 Metodo para determinar el riesgo de recidiva de cancer de mama.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016002938A MX2016002938A (es) 2013-09-11 2014-09-10 Prediccion de la recidiva del cáncer de mama.

Country Status (10)

Country Link
US (2) US20150203921A1 (es)
EP (1) EP3044335B1 (es)
JP (1) JP2016536004A (es)
CN (1) CN105722998A (es)
BR (1) BR112016005225B1 (es)
CA (1) CA2923606A1 (es)
ES (1) ES2829912T3 (es)
IL (2) IL244554B (es)
MX (2) MX2016002938A (es)
WO (1) WO2015038682A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
ES2667547T3 (es) 2010-12-09 2018-05-11 Biotheranostics, Inc. Pronóstico de cáncer de mama después del tratamiento
IL259241B2 (en) * 2015-11-13 2024-04-01 Biotheranostics Inc Combination of tumor characteristics with breast cancer index
AU2019321588A1 (en) 2018-08-17 2021-03-04 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
CN112646890A (zh) * 2020-12-29 2021-04-13 郑鸿钧 用于预测早期乳腺癌远处复发风险的多基因检测引物
WO2024073659A1 (en) * 2022-09-30 2024-04-04 Biotheranostics, Inc. Biomarker assay to select breast cancer therapy
CN117476246B (zh) * 2023-12-25 2024-04-19 福建大数据一级开发有限公司 基于多类型复发事件的患者生存分析方法、介质及装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
WO2000029044A2 (en) 1998-11-13 2000-05-25 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
CA2539107A1 (en) 2003-09-19 2005-03-31 Arcturus Bioscience, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
WO2009108215A1 (en) 2007-09-06 2009-09-03 Aviaradx, Inc. Tumor grading and cancer prognosis
CA2793133C (en) * 2010-03-31 2019-08-20 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
ES2667547T3 (es) 2010-12-09 2018-05-11 Biotheranostics, Inc. Pronóstico de cáncer de mama después del tratamiento
SG10202010758SA (en) * 2011-11-08 2020-11-27 Genomic Health Inc Method of predicting breast cancer prognosis

Also Published As

Publication number Publication date
ES2829912T3 (es) 2021-06-02
IL276505B (en) 2022-03-01
EP3044335A4 (en) 2017-04-19
IL244554A0 (en) 2016-04-21
EP3044335A1 (en) 2016-07-20
US20150203921A1 (en) 2015-07-23
BR112016005225B1 (pt) 2023-11-14
MX2016002938A (es) 2016-07-26
WO2015038682A1 (en) 2015-03-19
CN105722998A (zh) 2016-06-29
CA2923606A1 (en) 2015-03-19
IL244554B (en) 2020-08-31
US20220186317A1 (en) 2022-06-16
EP3044335B1 (en) 2020-09-09
IL276505A (en) 2020-09-30
BR112016005225A2 (es) 2017-08-01
JP2016536004A (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
MX2021002014A (es) Metodo para determinar el riesgo de recidiva de cancer de mama.
IL236336A0 (en) Methods of treating breast cancer with gemcitabine therapy
SG11201607448PA (en) Determining cancer agressiveness, prognosis and responsiveness to treatment
IL244421A0 (en) Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy
PH12018502570A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EP2852689A4 (en) NANO-46 GENES AND METHODS FOR PREDICTING EVOLUTION OF BREAST CANCER
SG11201508585PA (en) Enhanced adoptive cell therapy
EP2968191A4 (en) METHOD FOR THE TREATMENT OF BUBBLE CANCER
IL248487A0 (en) Methods for treating early breast cancer with trastuzumab-dmi-mcc and pertuzumab
IL252587A0 (en) A method for predicting response to substances for the treatment of breast cancer, and a method for the treatment of breast cancer
IL239007A0 (en) Use of Aribolin to treat breast cancer
HK1222888A1 (zh) 預測在淋巴結陽性早期乳癌復發風險的方法
EP2959291A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER BY DETECTION AND MANIPULATION OF MICROBES IN TUMORS
HK1213817A1 (zh) 治療癌症的方法
HK1220253A1 (zh) 診斷前列腺癌症的方法
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
HK1219513A1 (zh) 治療癌症的方法
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
EP2888594A4 (en) METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER
EP2870480A4 (en) METHOD FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER
IL252639A0 (en) Breast cancer treatment using taxane
GB2519829B (en) Methods for monitoring treatment response and relapse in breast cancer
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
GB201610362D0 (en) Predicting responsiveness to therapy in prostate cancer